HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

500.565

-23.308-4.45%

Number of Gainers:4

Number of Losers:26

Number of Flat:3

PE:- -

High:523.582

Open:523.582

Low:499.109

Close:523.873

Volume:46.13M

Turnover:1.38B

Market Cap:321.19B

Float Cap:284.66B

Loading ...

Healthcare Sector Sees Continued Positive Signals; CCB Fund Manager Liang Furui Highlights High-Prosperity Areas Such as Innovative Drugs

Zhaoke Ophthalmology (SEHK:6622) Stock Carries A 34.7x P/S Under Heavy Losses

Simply Wall St.

Ascletis Announces First Participant Dosed in a Global Phase Iii Clinical Program of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist Asc30 for Chronic Weight Management

THOMSON REUTERS

Ascletis Pharma - Topline Phase Iii Data Expected Q3 2028; FDA Nda by End 2028; Ema Maa Early 2029

THOMSON REUTERS

Three New Share Subscriptions Next Week Spanning AI Chip and Innovative Drug Hotspots; Nine IPOs This Year Have Already Delivered Over 100,000 Yuan Profit Per Lot

Ocumension Therapeutics (SEHK:1477) Stock Growth Story Runs Into Funding Risk

Simply Wall St.

Bai Hua Pharma's Surge Halts After Doubling Within a Month, Company Clarifies Innovation Drug CRO Remains Minimal

OCUMENSION-B (01477) reports 57.5M yuan adjusted net loss for the first half, narrowing by 46.74% year-on-year

BASECARE-B Reports 40.7% Narrower Interim Net Loss

Transcenta-B Reports Mid-Year Results: Net Loss Narrows 38.66% to RMB 67.3 Million

Zhaoke Ophthalmology's Half-Year Results: Net Loss Widens to RMB 123 Million Amid Rising Costs

China's Ocumension Therapeutics H1 Revenue Surges on Higher Ophthalmic Product Sales

Ocumension Therapeutics Shifts Hk$102.5 Million IPO Proceeds to Working Capital, General Corporate Uses

Ocumension Therapeutics FY26 H1 Net Loss Narrows 25.2% to RMB 99.02 Million; Revenue Rises 44.1% to RMB 423.7 Million

Ocumension Therapeutics - Board Does not Recommend Distribution of an Interim Dividend

THOMSON REUTERS

Ocumension Therapeutics - Adjusted Net Loss Narrowed by 46.7% to Rmb57.5 Mln for Six Months

THOMSON REUTERS

Alphamab Oncology - Board Resolves to Repurchase Shares up to HK$80 Mln in Value

THOMSON REUTERS

Alphamab Oncology Launches On-Market Share Buyback of up to HK$ 80 Million

EDDING GENOR Reports Interim Loss, Swinging to Deficit in First Half

China's Zhaoke Ophthalmology H1 Revenue Rises

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":500.5648,"timestamp":1788145551669,"preClose":523.8731,"halted":0,"volume":46125944,"delay":0,"changeRate":-0.044492,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-23.308319,"latestTime":"08-31 11:05:51","open":523.582,"high":523.582,"low":499.10938,"amount":1382984871,"amplitude":0.046715,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1788148800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":3.909696,"peRate":137.956161,"turnoverRate":0.001674,"increases":4,"decrements":26,"flats":3,"marketCap":321192026096,"floatMarketCap":284657040136},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":523.582,"amplitude":0.046715,"preClose":523.8731,"low":499.10938,"pbRate":"3.909696","latestPrice":500.5648,"volume":46126044,"delay":0,"open":523.582,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":496.742,"twentyDayClose":467.18,"sixtyDayClose":475.465,"secType":"PLATE","market":"HK","turnoverRate":0.001674,"peRate":137.956161,"marketCap":321192026096,"floatMarketCap":284657040136,"timestamp":1788145551698,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":4,"down":26,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1170146874","title":"Healthcare Sector Sees Continued Positive Signals; CCB Fund Manager Liang Furui Highlights High-Prosperity Areas Such as Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1170146874","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170146874?lang=en_us&edition=fundamental","pubTime":"2026-08-31 09:31","pubTimestamp":1788139881,"startTime":"0","endTime":"0","summary":"A wave of encouraging signals has recently emerged across the healthcare industry. The National Healthcare Security Administration and the National Medical Products Administration have coordinated...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BK1574","06978","BK1161","159992","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663266430","title":"Zhaoke Ophthalmology (SEHK:6622) Stock Carries A 34.7x P/S Under Heavy Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663266430","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663266430?lang=en_us&edition=fundamental","pubTime":"2026-08-31 06:36","pubTimestamp":1788129366,"startTime":"0","endTime":"0","summary":"Traders kept Zhaoke Ophthalmology almost flat coming into the H1 2026 report, with the stock up only about 2% over the past week. The calm price action contrasts with a much more charged reality. The company is still posting heavy losses, with H1 basic earnings per share at a loss of ¥0.22 and a net loss of ¥122.6 million.\nThe key issue is valuation. Zhaoke Ophthalmology trades on a P/S multiple of 34.7x, compared with the Hong Kong pharmaceuticals average near 2x. This puts every line of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6622/zhaoke-ophthalmology-shares/news/zhaoke-ophthalmology-sehk6622-stock-carries-a-347x-ps-under","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6622/zhaoke-ophthalmology-shares/news/zhaoke-ophthalmology-sehk6622-stock-carries-a-347x-ps-under","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1587","06622","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663041570","title":"Ascletis Announces First Participant Dosed in a Global Phase Iii Clinical Program of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist Asc30 for Chronic Weight Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2663041570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663041570?lang=en_us&edition=fundamental","pubTime":"2026-08-30 18:15","pubTimestamp":1788084903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nTUAB84DSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1515","01672","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663041506","title":"Ascletis Pharma - Topline Phase Iii Data Expected Q3 2028; FDA Nda by End 2028; Ema Maa Early 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2663041506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663041506?lang=en_us&edition=fundamental","pubTime":"2026-08-30 18:15","pubTimestamp":1788084903,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nTUAB84DSR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","01672","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120832388","title":"Three New Share Subscriptions Next Week Spanning AI Chip and Innovative Drug Hotspots; Nine IPOs This Year Have Already Delivered Over 100,000 Yuan Profit Per Lot","url":"https://stock-news.laohu8.com/highlight/detail?id=1120832388","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120832388?lang=en_us&edition=fundamental","pubTime":"2026-08-30 14:30","pubTimestamp":1788071447,"startTime":"0","endTime":"0","summary":"The new share market has remained active this week. On Tuesday (August 25), Gaoke Technology made its debut on the STAR Market with an issue price of 61.36 yuan per share. The stock peaked at 262...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVS","BK1161","AVGW","GPTZ","AVGX","IBBQ","LRNZ","AIFD","AVL","AVGG","EPAI","03191","159992","AIS","AIBU","LNGR","FAI","ALAI","AVGC","WISE","AIVC","AVGU","MEDX","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663820048","title":"Ocumension Therapeutics (SEHK:1477) Stock Growth Story Runs Into Funding Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2663820048","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663820048?lang=en_us&edition=fundamental","pubTime":"2026-08-30 04:26","pubTimestamp":1788035199,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics walked into this earnings season with a growth story and a stock that had drifted over the past three months, down about 14.5%, yet roughly flat over the week and modestly firmer over the month. The headline today is not revenue; it is the pressure on the income statement. H1 2026 brought a net loss of C¥99.0 million and basic earnings per share of C¥0.12 loss, keeping profitability out of reach and sharpening investor focus on how long the company can fund its...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1477/ocumension-therapeutics-shares/news/ocumension-therapeutics-sehk1477-stock-growth-story-runs-int","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1477/ocumension-therapeutics-shares/news/ocumension-therapeutics-sehk1477-stock-growth-story-runs-int","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK4007","01477","BK1191","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137049499","title":"Bai Hua Pharma's Surge Halts After Doubling Within a Month, Company Clarifies Innovation Drug CRO Remains Minimal","url":"https://stock-news.laohu8.com/highlight/detail?id=1137049499","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137049499?lang=en_us&edition=fundamental","pubTime":"2026-08-29 13:50","pubTimestamp":1787982621,"startTime":"0","endTime":"0","summary":"On August 28, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. hit the daily limit down during intraday trading. Wind data shows that by the close of trading on August 28, the company's shares settled at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600721","BK0102","159992","LNGR","MEDX","BK0216","IBBQ","BK1161","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145067140","title":"OCUMENSION-B (01477) reports 57.5M yuan adjusted net loss for the first half, narrowing by 46.74% year-on-year","url":"https://stock-news.laohu8.com/highlight/detail?id=1145067140","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145067140?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:08","pubTimestamp":1787933296,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) has published its interim results for the six months ended June 30, 2026. The group recorded revenue of 424 million yuan, representing a year-on-year increase of 44.1%. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110812788","title":"BASECARE-B Reports 40.7% Narrower Interim Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1110812788","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110812788?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:56","pubTimestamp":1787928990,"startTime":"0","endTime":"0","summary":"BASECARE-B (02170) has announced its interim results for the six months ended June 30, 2026, with group revenue reaching RMB 129 million, marking a 27.05% increase year-on-year.The company's net loss...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170","BK1597","BK1574","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108926972","title":"Transcenta-B Reports Mid-Year Results: Net Loss Narrows 38.66% to RMB 67.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1108926972","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108926972?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:53","pubTimestamp":1787928839,"startTime":"0","endTime":"0","summary":"Transcenta-B (06628) has published its interim financial results for the six-month period ended June 30, 2026. The company recorded revenue of RMB 23.6 million, representing a substantial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","09939","BK1574","06628","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143245213","title":"Zhaoke Ophthalmology's Half-Year Results: Net Loss Widens to RMB 123 Million Amid Rising Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=1143245213","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143245213?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:53","pubTimestamp":1787928836,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology-B (06622) has released its interim results for the 2026 fiscal year, showing total revenue of RMB 18.828 million, a year-on-year increase of 19.14%. However, the company recorded...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","06622","BK1191","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099200","title":"China's Ocumension Therapeutics H1 Revenue Surges on Higher Ophthalmic Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099200","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099200?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:24","pubTimestamp":1787927067,"startTime":"0","endTime":"0","summary":"China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product salesOverviewChina ophthalmic pharma firm's half-year revenue rose 44.1% yr/yr to RMB423.7 mlnAdjusted net loss narrowed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02219","BK1191","BK1583","06622","BK1209","01477","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099255","title":"Ocumension Therapeutics Shifts Hk$102.5 Million IPO Proceeds to Working Capital, General Corporate Uses","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099255?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:21","pubTimestamp":1787926882,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics shifts HK$102.5 million IPO proceeds to working capital, general corporate usesOcumension shifted capital planning toward broader commercial operations, reallocating remaining ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL60mWRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099986","title":"Ocumension Therapeutics FY26 H1 Net Loss Narrows 25.2% to RMB 99.02 Million; Revenue Rises 44.1% to RMB 423.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099986","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099986?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:15","pubTimestamp":1787926549,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics FY26 H1 net loss narrows 25.2% to RMB 99.02 million; revenue rises 44.1% to RMB 423.7 millionOcumension Therapeutics revenue rose 44.1% to RMB 423.7 million for the six months ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLbKvvMw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662999470","title":"Ocumension Therapeutics - Board Does not Recommend Distribution of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662999470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662999470?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:15","pubTimestamp":1787926532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1VM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099671","title":"Ocumension Therapeutics - Adjusted Net Loss Narrowed by 46.7% to Rmb57.5 Mln for Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099671?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:15","pubTimestamp":1787926532,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662096191","title":"Alphamab Oncology - Board Resolves to Repurchase Shares up to HK$80 Mln in Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2662096191","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662096191?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:56","pubTimestamp":1787925376,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1XZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662509616","title":"Alphamab Oncology Launches On-Market Share Buyback of up to HK$ 80 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662509616","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662509616?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:55","pubTimestamp":1787925346,"startTime":"0","endTime":"0","summary":"Alphamab Oncology launches on-market share buyback of up to HK$ 80 millionAlphamab Oncology authorized an on-market share buyback of up to HK$80 million, starting Aug. 28, 2026.Repurchases will be fun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL21zqMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171474901","title":"EDDING GENOR Reports Interim Loss, Swinging to Deficit in First Half","url":"https://stock-news.laohu8.com/highlight/detail?id=1171474901","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171474901?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:50","pubTimestamp":1787925016,"startTime":"0","endTime":"0","summary":"EDDING GENOR (06998) has announced its financial results for the six-month period ended June 30, 2026, revealing a notable shift from profitability to a net loss.During the reporting period, the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","06998","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662951720","title":"China's Zhaoke Ophthalmology H1 Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2662951720","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662951720?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:24","pubTimestamp":1787923484,"startTime":"0","endTime":"0","summary":"China's Zhaoke Ophthalmology H1 revenue risesOverviewChina ophthalmic drug maker's interim revenue rose yr/yr to RMB 18.8 mlnNon-HKFRS adjusted loss for the period widened slightly to RMB 116.1 mlnCom","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","02219","BK1583","BK1574","BK1209","02616","06622","BK1589","BK1191","BK1161","03692"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":1,"totalSize":346,"code":"91000000","status":"200"}]}}